Cardiovascular and Metabolic

Driven by Our Research

CSL is committed to developing novel therapies that save and improve the lives of patients with life-threatening diseases. As part of this commitment, we have established a Therapeutic Area that focuses on the #1 cause of death worldwide: Cardiovascular and Metabolic (CV&M) disease.

Our goal is to address areas of high, unmet medical need, and we strive to develop new approaches that will greatly improve how we treat these significant global health concerns.

We have assembled a global team of CV&M experts who have capabilities spanning across all phases of development. On behalf of the entire team, thank you for your interest in CSL Cardiovascular and Metabolic. We're looking forward to sharing our continued contribution to the science.

Congress Materials

AHA 2022 | November 5–7, 2022 | View Materials
ESC 2022 | August 26–29, 2022 | View Materials
ACC 2022 | April 2–4, 2022 | View Materials
AHA 2021 | November 13–15, 2021 | View Materials
ESC 2021 | August 27–30, 2021 | View Materials
ACC 2021 | May 15–17, 2021 | View Materials
AHA 2020 | November 13–17, 2020 | View Materials

Watch video

Meet Us at an Event

American Heart Association (AHA) Scientific Sessions	November 5–7, 2022	Chicago, IL USA	Details
American College of Cardiology (ACC) Scientific Sessions	March 4–6, 2023	New Orleans, LA USA	Details

Cardiovascular and Metabolic Resources

Disease Education Website

Learn how cholesterol efflux may reduce the risk of recurrent cardiovascular events

Click Here to Discover Cholesterol Efflux

CMD-CRP-0001
January 2023